Consideration of Alternative Licensing Procedures for Vaccines for Minor Species, Minor Indications and Autogenous/Autologous Products

PEI Lecture Hall, Langen, Germany
October 29 – 31, 2003

Volume editor
Carmen Junghäck
Paul-Ehrlich-Institut, Langen, Germany

Proceedings of a meeting organized by the
International Association for Biologicals (IABs), and the
Paul-Ehrlich-Institut (PEI)

11 figures and 25 tables, 2004
## Contents

### Opening Speech

**Opportunities and Expectations**  
*D.A. Espeseth*  
3

### Session I (Part 1)

**Autogenous/Autologous Vaccines**

**Legal Basis and Definitions: Views from Authorities, Field and Industry**  
Moderator: *Carmen Jungbäck (PEI)*  
7

- Regulation of Autogenous Biologicals in the United States  
  *C.S. Schmelik-Sundage, R.E. Hill, Jr.*  
  9

- Autogenous Vaccines: the Legal Basis and Regulation in the United Kingdom  
  *M. Ilott*  
  15

- Veterinary Autogenous Vaccines  
  *A. Hera, J. Bures*  
  19

- Autogenous Vaccines: Industry Proposals for Procedures and Requirements  
  *S. Zänker*  
  27

### Session I (Part 2)

**Autogenous/Autologous Vaccines**

**Identification of Suitable and Needed Antigens and Criteria for Quality of Production and Control**  
Moderator: *Richard Hill (CVB, USDA, APHIS)*  
31

- Autologous Biologicals – Science/Regulations  
  *M.L. Chapek, K.K. Brown, B.C. Lin*  
  33

- Autogenous Vaccines: Determining Product Need and Antigen Selection, Production and Testing Considerations  
  *H.A. Draayer*  
  43

- The Manufacture of Autogenous Vaccines in France  
  *C. Miras*  
  49

- Current Concepts and Future Approaches to the Development of Autologous/Autogenous Vaccines for Veterinary Use  
  *M. Tollis*  
  55
Session I (Part 3)

Autogenous/Autologous Vaccines

Actual Situation and Handling in the Field: Producers' and Users' Point of View .......................... 61
Moderator: Brigitte Bönisch (Merial)

Autogenous Vaccines: Current Use Patterns and End Users' Needs in the Integrated Broiler Industry
J.A. Smith

Autogenous Vaccines: Current Use in the Field in the U.S. Cattle and Hog Industry .................... 69
C.C.L. Chase

Current Situation and Use of Autogenous Vaccines in France: The Views of the Manufacturer
and the User ............................................................................................................................................... 73
E. Thibault

Manufacturing and Use of Autologous Vaccines in Germany – Experience of a Vaccine Manufacturer
A. Neubert

Session II (Part 1)

Vaccines for Minor Use and Minor Species

Introduction, Producers' and Veterinarians' Point of View ............................................................... 87
Moderator: David Mackay (Laboratory Institute for Animal Health)

Minor Species/Minor Indications – Introductory Remarks .................................................................. 89
C. Junghäck

Minor Species, Who Cares? ..................................................................................................................... 93
M.M.L. Aerts

Conditional Licensing of Veterinary Biologicals in the United States: a Major Manufacturer's
Perspective ................................................................................................................................................. 97
M.M. Carlson, Y.-W. Chiang, H.-J. Chu

Vaccines for Minor Use and Minor Species (MUMS) – Industry's Views ............................................ 105
B. Bönisch

A Small Manufacturer's Perspective on Small Volume Products .......................................................... 111
J.N. Huff

Consideration of Alternative Licensing Procedures for Vaccines for Minor Species and Minor
Indications – Manufacturer's Point of View ............................................................................................. 117
J. de Foucauld

Vaccine Use and Abuse: a Practitioner's Viewpoint .............................................................................. 123
G.A. Moore

Session II (Part 2)

Vaccines for Minor Use and Minor Species

Necessary Changes in Legal Provisions ................................................................................................. 129
Moderator: Peter Jones (EMEA)

Minor Species/Minor Indications: Legal Provisions, Definition Criteria and Policies
to Be Considered ....................................................................................................................................... 131
O. Papadopoulos

Vaccines for Minor Use and Minor Species: Technical Difficulties to Solve and Consequences
in Legal Definitions .................................................................................................................................. 137
P. Vannier

Vaccines for Minor Use/Minor Species (MUMS) in the European Union ............................................. 141
D. Mackay
Session II (Part 3)

Vaccines for Minor Use and Minor Species

Legal Basis, Definitions, Need for Availability and the Role of Conditional Licences: Authorities' Point of View

Moderator: Manfred Moos (PEI)

Regulation of Conditionally Licensed Biologicals in the United States

R.E. Hill

Consideration of Alternative Licensing Procedures for Vaccines for Minor Species, Minor Indications and Autogenous/Autologous Products

P.G.H. Jones

Use of Vaccines for Minor Species – Minor Indications

T. Sods

Vaccines for Minor Species and Minor Indications: Current Situation and Concepts in Germany – Feasible Approaches for the Future – Authorities' View

E. Werner